Drug Profile
Research programme: histone deacetylase inhibitors - EntreMed
Alternative Names: MKC-1313Latest Information Update: 19 Dec 2008
Price :
$50
*
At a glance
- Originator Miikana Therapeutics
- Developer EntreMed
- Class
- Mechanism of Action Apoptosis stimulants; Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Dec 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 13 Jul 2007 Preclinical trials in Cancer in USA (unspecified route)